Sign in Cart 0 Shop peptides
Orders placed and paid for before 2pm, Monday to Friday, are despatched the same day on Royal Mail Tracked 24.
Cagrilintide 10mg

Cagrilintide 10mg

£120.00

An amylin analogue studied in satiety and metabolic-signalling research.

Specifications
Strength
10 mg
Format
Lyophilised powder
Purity
98.3% (HPLC, batch Ca10-20250818)
Certificate of analysis
Included with every batch
Storage
2–8°C, away from light
Dispatch
Tracked, from the UK

In stock

Includes 1 × bacteriostatic water (reconstitution diluent), free with every vial.

SKU: TAD-CAGRI-10 Category:
  • Tracked UK dispatch
  • Discreet packaging
  • Certificate of analysis
  • Secure checkout
Download spec & handling sheet (PDF)
Download Certificate of Analysis (PDF)

Batch certificate: appearance, HPLC purity, assay, water content, sterility & endotoxin results.

Description

Cagrilintide is an acylated, long-acting analogue of amylin — a hormone co-secreted with insulin from pancreatic beta cells. In research it is studied as an amylin-receptor agonist for its role in satiety signalling, gastric-emptying and glucagon regulation via central amylin receptors, and its lipid modification, which extends its half-life, is of interest in long-acting peptide research. Supplied strictly for laboratory research use only — not for human or veterinary use.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Selected published research
The references below are provided solely for scientific and research context. They describe published laboratory, cell-culture and preclinical research into this compound and related chemistry. They are not claims that this product has any effect in humans or animals, are not medical, therapeutic or dosing guidance, and do not describe an intended use. TAD products are supplied strictly for laboratory research use only.
  1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160–2172.
  2. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. 2021;397(10286):1736–1748.

Related products

Certificate of analysis
Tracked UK dispatch
Discreet packaging
Secure checkout
For laboratory research use only. Not for human or veterinary consumption.